Learn what atogepant is, how this oral CGRP receptor antagonist works, and why migraine specialists are excited about its once‑daily dosing and clinical trial results for episodic and chronic migraine prevention.
Learn what zavegepant is, how its intranasal CGRP receptor blockade works, and why it’s emerging as a fast, needle‑free option for acute migraine relief and prevention.
Learn how atogepant, an oral CGRP receptor antagonist, is redefining migraine prevention. Explore its mechanism of action, benefits over traditional therapies, safety profile, clinical data, and its future role in personalized, AI-assisted migraine management.
Learn how zavegepant, the first intranasal CGRP receptor antagonist, offers fast-acting, targeted relief for acute migraine—especially for patients who can’t tolerate oral medications or need rapid onset of action.